Think of any Boots. All their script meds, huge database manifests of names - same old plot about how vendors get their volume of sales shares just exactly right for regional distribution, who funds postgrad research degrees at specific unis, which palms get greased by demographic “science”
Side note, Actavis is a good case study for compounds like benzos, lot of money at stake with scripts being smashed out and increasing with Covid. If they undersupply just enough, they can keep the price where they want. Just blame Brexit. How this market model is allowed to pressure public services was a point Corbyn got right, targeting patent reform. Sorry Jez, lagers in Greenwich
Be interesting to see if any health boards make patient record rejection a regional legal default precedent (did it for organ donors). Build an unfolding policy for primary care that could then be rolled out nationally. It can be that simple and that easily exploited